Long COVID hallmarks on [18F]FDG-PET/CT: a case-control study.
Brain hypometabolism
Chronic COVID syndrome
Infection
Inflammation
Long COVID
SARS-CoV-2
[18F]FDG PET/CT
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
09
01
2021
accepted:
01
03
2021
pubmed:
8
3
2021
medline:
14
9
2021
entrez:
7
3
2021
Statut:
ppublish
Résumé
The present study hypothesised that whole-body [18F]FDG-PET/CT might provide insight into the pathophysiology of long COVID. We prospectively enrolled 13 adult long COVID patients who complained for at least one persistent symptom for >30 days after infection recovery. A group of 26 melanoma patients with negative PET/CT matched for sex/age was used as controls (2:1 control to case ratio). Qualitative and semi-quantitative analysis of whole-body images was performed. Fisher exact and Mann-Whitney tests were applied to test differences between the two groups. Voxel-based analysis was performed to compare brain metabolism in cases and controls. Cases were further grouped according to prevalent symptoms and analysed accordingly. In 4/13 long COVID patients, CT images showed lung abnormalities presenting mild [18F]FDG uptake. Many healthy organs/parenchyma SUVs and SUV ratios significantly differed between the two groups (p ≤ 0.05). Long COVID patients exhibited brain hypometabolism in the right parahippocampal gyrus and thalamus (uncorrected p < 0.001 at voxel level). Specific area(s) of hypometabolism characterised patients with persistent anosmia/ageusia, fatigue, and vascular uptake (uncorrected p < 0.005 at voxel level). [18F]FDG PET/CT acknowledged the multi-organ nature of long COVID, supporting the hypothesis of underlying systemic inflammation. Whole-body images showed increased [18F]FDG uptake in several "target" and "non-target" tissues. We found a typical pattern of brain hypometabolism associated with persistent complaints at the PET time, suggesting a different temporal sequence for brain and whole-body inflammatory changes. This evidence underlined the potential value of whole-body [18F]FDG PET in disclosing the pathophysiology of long COVID.
Identifiants
pubmed: 33677642
doi: 10.1007/s00259-021-05294-3
pii: 10.1007/s00259-021-05294-3
pmc: PMC7937050
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3187-3197Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
J Nucl Med. 2015 Apr;56(4):575-9
pubmed: 25745092
Eur Heart J. 2020 Sep 1;41(32):3038-3044
pubmed: 32882706
Forensic Sci Med Pathol. 2021 Jun;17(2):279-296
pubmed: 33026628
MMWR Morb Mortal Wkly Rep. 2020 Oct 09;69(40):1450-1456
pubmed: 33031361
Lancet Infect Dis. 2020 Nov;20(11):e276-e288
pubmed: 32818434
Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2823-2833
pubmed: 33501506
Nat Med. 2020 Dec;26(12):1803
pubmed: 33288947
Brain. 2018 Aug 1;141(8):2272-2279
pubmed: 30730551
BMJ. 2020 Aug 11;370:m3026
pubmed: 32784198
Eur J Nucl Med Mol Imaging. 2005 Dec;32(12):1406-11
pubmed: 16133379
Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):592-595
pubmed: 32728799
Eur J Neurol. 2020 Dec;27(12):2651-2657
pubmed: 32881133
Nat Rev Cardiol. 2018 Sep;15(9):505-522
pubmed: 30065258
Neuroinformatics. 2014 Oct;12(4):575-93
pubmed: 24952892
Pharmaceuticals (Basel). 2020 Nov 10;13(11):
pubmed: 33182811
Soc Cogn Affect Neurosci. 2009 Dec;4(4):423-8
pubmed: 20035017
J Nucl Med. 2013 Apr;54(4):647-58
pubmed: 23359660
J Biomed Inform. 2014 Apr;48:193-204
pubmed: 24582925
J Thromb Thrombolysis. 2020 Oct;50(3):499-511
pubmed: 32700024
Acad Radiol. 2020 Jul;27(7):1042-1043
pubmed: 32386948
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1467-1477
pubmed: 33106925
J Thromb Thrombolysis. 2020 Jul;50(1):54-67
pubmed: 32415579
East Asian Arch Psychiatry. 2014 Mar;24(1):37-8
pubmed: 24676486
Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1250-1269
pubmed: 29637252
Radiographics. 2005 Sep-Oct;25(5):1357-68
pubmed: 16160116
Eur J Nucl Med Mol Imaging. 2021 Jul;48(8):2543-2557
pubmed: 33452633
Neuroimage. 2011 Jan 1;54(1):142-7
pubmed: 20682349
Lung Cancer. 2014 Aug;85(2):205-12
pubmed: 24854401
Eur J Nucl Med Mol Imaging. 2021 Jul;48(8):2531-2542
pubmed: 33420914
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1460-1466
pubmed: 33123760
J Virol. 2017 Oct 13;91(21):
pubmed: 28814515
EJNMMI Res. 2015 Dec;5(1):65
pubmed: 26573211
Brain. 2005 Aug;128(Pt 8):1764-77
pubmed: 15888538
Chin Med J (Engl). 2020 May 5;133(9):1039-1043
pubmed: 32118639
Lancet. 2020 Dec 12;396(10266):1861
pubmed: 33308453
Contrast Media Mol Imaging. 2019 Jul 25;2019:3018349
pubmed: 31427907
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1281-1286
pubmed: 32088847